kezar life sciences news

Kezar Life Sciences Inc KZR shares closed today at 07 below its 52 week high of 1634 giving the company a market cap of 775M. KZR shares are trading higher by 50 at 1608 after HC Wainwright Co.

Pin On What S Going On

KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments.

. Kezar Life Sciences Inc. Kezar Life Sciences Inc. Recent News View All News.

Maintained a Buy rating on the stock and raised its price target from 20 to 22. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. SOUTH SAN FRANCISCO Calif May 12 2022 -- BUSINESS WIRE -- Kezar Life Sciences Inc.

Kezar Life Sciences climbs after over 1 million insider purchase. NASDAQKZR insiders still down US17k after a US13m shopping spree. Estimates by analysts give the company expected earnings per share EPS of -03 with the EPS growth for the year raised at -123 for 2022 and -129 for next year.

This is a 4 percent decrease over losses of 025 per share from the same period last year. Berger acquired 60000 shares of the firms stock in a transaction dated Friday March 18th. BioMarin FDA Decision Tapering Earnings News.

Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022 consistent with previous guidance. Kezar Life Sciences KZR-616 an Orphan Drug in US. Kezar Life Sciences Inc.

When the trading was stopped its value was 663Recently in News on May 12 2022 Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update. NASDAQKZR insiders still down US17k after a US13m shopping spree. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences rises 66 on phase 2 data for lupus candidate Benzinga 167d The Week Ahead In Biotech Nov. Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar slumps as top-line results from zetomipzomib trial disappoint.

On average they anticipate Kezar Life Sciences stock price to reach 1667 in the next year. Their forecasts range from 1400 to 2200. Possible turnaround for Kezar Life Sciences Inc.

23 2020 Encouraging lupus data lifts Kezar Life Sciences up 9 after hours. KZR a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated. In related news Director Franklin M.

Today Kezar Life Sciences Inc NASDAQKZR lost 041 to end the day Thursday at 549. Wells Fargo Company reduced their price objective on shares of Kezar Life Sciences from 1900 to 1400 in a research report on Wednesday May 4th. 3 brokers have issued 12-month price targets for Kezar Life Sciences shares.

SOUTH SAN FRANCISCO Calif March 17 2022--Kezar Life Sciences Inc Nasdaq. Possible turnaround for Kezar Life Sciences Inc. Is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San.

Shares of clinical-stage drug developer Kezar Life Sciences plunged more than 24 to 935 in after-hours trading on Tuesday as the company announced mixed top-line results from the PRESIDIO Phase II clinical trial of zetomipzomib formerly KZR-616 in patients with. Kezar Life Sciences Inc. Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635c4 May 5 2022 430pm EDT.

Kezar Life Sciences Inc NASDAQ. This suggests a possible upside of 1998 from the stocks current price. The company is pioneering first-in-class small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single powerful targets.

Kezar Life Sciences NASDAQKZR - Get Rating announced its quarterly earnings data on Thursday. Kezar Life Sciences NASDAQKZR reported quarterly losses of 026 per share. For autoimmune inflammatory disorders SA News Fri Oct.

Has a market cap of 38441 million and is expected to release its quarterly earnings report on Mar 09 2022 Mar 14 2022. The stock is currently up 2023 year-to-date up 1833 over the past 12 months and down 111 over the past five years. Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635c4 May 5 2022 430pm EDT.

The company reported 026 EPS for the quarter beating analysts consensus estimates of 028 by 002. Nov 15 2021 405pm EST. The company opened at 594 and shares fluctuated between 607 and 549 with 1656088 shares trading.

A number of research firms have commented on KZR. Kezar Life Sciences Inc. Some of the losses seen.

4000 Shoreline Court Suite 300 South San Francisco CA 94080 T. Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis. Kezar Life Sciences Inc.

Potential Lupus Therapy Hcdr1 Granted A European Union Patent Lupus Clinical Trials Therapy